The lawsuit asserts that Defendants Cephalon, Inc., Teva Pharmaceutical Industries, Ltd.,
Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals, Inc. (collectively, “Cephalon”), Mylan
Pharmaceuticals Inc. and Mylan, Inc. (formerly known as Mylan Laboratories, Inc.)
(collectively, “Mylan”), and Sun Pharmaceuticals Industries, Ltd., as successor in interest to
Ranbaxy Laboratories, Ltd. and Ranbaxy Pharmaceuticals, Inc., (collectively “Ranbaxy”)
violated state antitrust and consumer protection laws relating to the sale of the prescription
pharmaceutical Provigil. All Defendants have denied any wrongdoing.
A $48,000,000 Settlement has been reached between the End-Payor Class Plaintiffs
(consumers and third-party payors) and the Cephalon Defendants, a $14,377,600
Settlement with the Mylan Defendants, and a $3,500,000 Settlement with the Ranbaxy
Defendants. The three Settlements total $65,877,600.
How do I get a payment?
To be eligible to receive a payment if the Court approves the Settlements,
you must complete and submit a valid Claim Form by January 15, 2020.
No one is claiming that Provigil® or Modafinil is unsafe or ineffective.